10-Q: Ascend Wellness Holdings Q2 2026: Revenue Dip, Margin Gains, Tax Uncertainty

Ascend Wellness Holdings reported a slight revenue decrease in Q2 2026 compared to the prior year, but saw improved gross margins and operating profit, while navigating significant tax liabilities and the evolving cannabis regulatory landscape.

Summary

• Ascend Wellness Holdings (AWH) reported a 1% decrease in revenue for the three months ended June 30, 2026, totaling $126.1 million, compared to $127.3 million in the same period last year.
• Gross profit increased by 10% to $45.5 million, with gross margin improving to 36.1% from 32.5% year-over-year.
• Operating profit turned positive at $5.3 million for the quarter, a significant improvement from an operating loss of $1.0 million in Q2 2025.
• Net loss for the quarter was $9.8 million, an improvement from a net loss of $24.4 million in the prior year's quarter.
• Interest expense increased by 73% to $20.8 million, largely due to higher costs associated with finance leases.
• The company recognized a $5.7 million income tax benefit for the quarter, influenced by the rescheduling of cannabis to Schedule III and a release of $14.8 million from its uncertain tax position reserve.
• As of June 30, 2026, cash and cash equivalents stood at $67.0 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously negative due to continued net losses, increasing interest expenses, and significant contingent liabilities, despite some operational improvements and positive developments in cannabis rescheduling.

Positives

• Improved gross profit margin to 36.1% from 32.5% year-over-year, driven by a higher volume of company-produced products and a focus on higher-margin products.
• Achieved an operating profit of $5.3 million, a substantial turnaround from a $1.0 million operating loss in the prior year's quarter.
• Net loss significantly reduced to $9.8 million from $24.4 million in the comparable prior year period.
• The company recognized an income tax benefit of $5.7 million, partly due to the rescheduling of cannabis to Schedule III and a favorable settlement of uncertain tax positions.
• Acquisitions and consolidated partnership activity contributed incremental revenue, offsetting declines in legacy business segments.
• The company has $67.0 million in cash and cash equivalents, which management believes is adequate for the next twelve months.

Negatives

• Revenue decreased by 1% to $126.1 million for the quarter, primarily due to increased competition and pricing pressure in legacy markets.
• Interest expense increased significantly by 73% to $20.8 million, largely driven by higher finance lease costs.
• The company continues to carry a substantial accumulated deficit.
• Significant uncertainty remains regarding the full impact of cannabis rescheduling on tax positions and operations.
• A $17,000 settlement payment for a litigation matter was made in February 2026.
• The company faces ongoing legal proceedings, including an anticompetitive collusion lawsuit filed by the State of Ohio.

Risks

• The federal illegality of cannabis continues to pose risks, despite recent rescheduling efforts.
• Increased competition and pricing pressure in key markets are impacting revenue.
• The company's ability to raise additional capital on favorable terms is not assured.
• Uncertainty surrounding the implementation and impact of the April 2026 Order on cannabis rescheduling, particularly concerning IRC Section 280E.
• Potential for tax audit challenges related to cost allocations between medical and adult-use cannabis operations.
• The company is subject to various state and local regulations, with potential for fines, restrictions, or loss of permits.
• The State of Ohio has filed a complaint alleging anticompetitive collusion among MSOs.
• A work stoppage at the Barry, Illinois facility occurred in June 2026, with potential unknown impacts on Q3 2026 results.

Future Outlook

Management believes that current cash and cash equivalents, combined with anticipated cash flows from operating activities, are adequate to support operations for the next twelve months. The company may access capital markets for additional funding through debt and/or equity financings as needed. Future growth is expected to be driven by dispensary openings, cultivation facility expansions, and increased consumer demand. However, the company cannot guarantee success in its business plans or its ability to raise additional capital.

Management Comments

• Management believes that cash and cash equivalents, combined with anticipated cash flows from operating activities, is more than adequate to support operations for the next twelve months.
• Management may continue to access capital markets for additional funding through debt and/or equity financings to supplement future cash needs, as may be required.
• Management cannot provide any assurances that the Company will be successful in accomplishing its business plans.
• If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail certain of its operations until such time as additional capital becomes available.

Industry Context

StockSavvy.ai notes that Ascend Wellness Holdings operates in a highly regulated and evolving cannabis industry. The recent rescheduling of certain cannabis products to Schedule III by the DOJ presents both opportunities and uncertainties, particularly regarding tax implications under IRC Section 280E. The company's focus on limited license markets and multi-state operations positions it within a competitive landscape where regulatory changes and market dynamics significantly influence performance.

Comparison to Industry Standards

• The company's gross margin of 36.1% for Q2 2026 is within the typical range for multi-state cannabis operators, though specific comparisons depend on market mix and operational efficiency.
• The increase in interest expense, particularly related to finance leases, highlights a common challenge for capital-intensive cannabis businesses needing significant investment in facilities and equipment.
• The company's net loss, while reduced, is still a concern, reflecting the ongoing profitability challenges faced by many MSOs due to high operating costs, taxes, and regulatory burdens.
• The significant uncertain tax liability ($214.5 million) underscores the unique tax challenges within the cannabis industry, particularly the impact of IRC Section 280E, which is more severe than for most other industries.

Legal Proceedings

• Green Thumb Industries Arbitration Matter: Settled for $17,000 in February 2026.
• State of Ohio Complaint: Filed February 6, 2026, alleging anticompetitive collusion among MSOs. The company denies the claims and plans to contest the case.

Related Party Transactions

• No significant related party transactions were disclosed for the six months ended June 30, 2026, other than those related to Stockholders Equity (Deficit).

Stakeholder Impact

• Shareholders: Continued net losses and significant debt may impact shareholder value, though improved margins and potential tax benefits offer some positive outlook.
• Creditors: Increased interest expense and substantial liabilities require careful management of debt obligations.
• Employees: A work stoppage at the Illinois facility in June 2026 highlights potential labor relations challenges.
• Suppliers: Standard commercial relationships are maintained in the ordinary course of business.
• Customers: The company aims to provide safe, reliable, and high-quality products, with a revamped Ozone-branded product offering.

Next Steps

• Continue to focus on optimizing operations and evaluating expansion opportunities.
• Monitor and adapt to evolving cannabis regulations, particularly the impact of the April 2026 Order on rescheduling.
• Evaluate the potential impact of the Illinois work stoppage on third-quarter financial results.
• Pursue strategic acquisitions and partnerships to drive growth.
• Manage capital expenditures, with an anticipated $20 million in net capital expenditures for 2026.

Key Dates

Recommendation

Ascend Wellness Holdings shows signs of operational improvement with better margins and reduced net losses, but faces significant headwinds including increasing debt service costs, ongoing legal challenges, and substantial tax uncertainties related to the cannabis industry. While the potential benefits from cannabis rescheduling are noted, the lack of clarity and the continued federal illegality of adult-use cannabis temper optimism. The company's ability to navigate these complexities and secure future capital will be critical. Therefore, a 'hold' recommendation is appropriate, pending further clarity on regulatory impacts and sustained financial performance.

Keywords

cannabis, Ascend Wellness Holdings, multi-state operator, retail, wholesale, acquisitions, tax, regulatory